Advertisement
UK markets open in 5 hours 26 minutes
  • NIKKEI 225

    38,259.86
    +57.49 (+0.15%)
     
  • HANG SENG

    18,313.86
    0.00 (0.00%)
     
  • CRUDE OIL

    79.28
    +0.29 (+0.37%)
     
  • GOLD FUTURES

    2,317.30
    -5.00 (-0.22%)
     
  • DOW

    39,056.39
    +172.13 (+0.44%)
     
  • Bitcoin GBP

    49,183.52
    -864.78 (-1.73%)
     
  • CMC Crypto 200

    1,309.70
    +15.03 (+1.16%)
     
  • NASDAQ Composite

    16,302.76
    -29.80 (-0.18%)
     
  • UK FTSE All Share

    4,544.24
    +21.25 (+0.47%)
     

Opthea to Present at the OIS Retina Innovation Summit at ARVO

Opthea Limited
Opthea Limited

MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, today announced that Dr. Frederic Guerard, Chief Executive Officer (CEO) of Opthea, will present the Company’s clinical-stage pipeline, as well as its innovation agenda, at the OIS Retina Innovation Summit prior to the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting on May 4, 2024 in Seattle, Washington.

OIS Retina Innovation Summit Details

Session

Innovation Showcase

Date:

Saturday, May 4, 2024

Time:

8:35 to 9:50 a.m. PDT

Presenter:

Frederic Guerard, PharmD, CEO

About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

ADVERTISEMENT

Opthea’s lead product candidate, sozinibercept, is being evaluated in two pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents. To learn more, visit our website and follow us on X and LinkedIn.

Authorized for release to ASX by Frederic Guerard, CEO 

Investor Inquiries

PJ Kelleher 
LifeSci Advisors, LLC 
Email: pkelleher@lifesciadvisors.com
Phone: 617-430-7579

Media Inquiries 

Silvana Guerci-Lena 
NorthStream Global Partners 
silvana@nsgpllc.com

Join our email database to receive program updates:  
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com